secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001628280-25-043489
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda reaches FDA framework to resolve disputes on HETLIOZ and tradipitant
--------------------------------------------------------------------------

- FDA expedited re-review of tradipitant clinical hold by Nov 26, 2025; PDUFA date Dec 30, 2025.
- FDA expedited re-review of HETLIOZ sNDA for jet lag by Jan 7, 2026; Part 12 proceedings paused.
- Vanda dismisses two lawsuits: one on tradipitant clinical hold (M.D. Fla.) and one on HETLIOZ info (S.D. Tex.).
- Both parties seek temporary pause of tradipitant gastroparesis administrative proceedings until Jan 7, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025043489/0001628280-25-043489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025043489/vnda-20251001.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-043489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer